Furthermore, a single-centre cohort study revealed that SGLT2 inhibitors positively influenced quality of life by reducing uric acid levels, pulmonary artery pressure, blood pressure, and NT-proBNP (N-terminal pro b-type natriuretic peptide), while increasing body mass index and left ventricular ejection fraction in patients with chronic heart failure. This evidence concerns the gene SLC5A2 and congestive heart failure.